Ibex receives CE mark for AI-powered solution for gastric cancer detection
Ibex Medical Analytics has obtained CE mark for Galen Gastric, an artificial intelligence-powered diagnostic solution for the detection of various types of gastric cancers, the company announced in a press release.
Galen Gastric is part of a suite of solutions that aids pathologists in the detection of gastric cancer, H. pylori and other clinical findings through quicker turnaround times and improved diagnostic workflows. The technology was developed by a team of pathologists, data scientists and software engineers.
According to the release, the CE mark was supported by results from a blinded, multisite clinical study, conducted at Medipath in France and Maccabi Healthcare Services in Israel, in which the AI-powered solution was highly accurate in the detection of various types of gastric cancer, H. pylori, neuroendocrine lesions, dysplasia, adenoma and other pathologies.
“Galen Gastric shines in two areas of patient care — more accurate cancer detection and shortened diagnostic turnaround time,” Judith Sandbank, MD, director of the Pathology Institute at Maccabi Healthcare Services, and principal investigator in the study, told Healio. “In both the clinical study for CE mark and in our everyday use of Galen in our lab, AI really proved it can help us more accurately diagnose gastric cancer, which is sometimes very small and not easily detectable. For additional indications such as H. Pylori, which is a common gastric infection and precursor for cancer, Galen Gastric can help improve the lab workflow by suggesting a diagnosis and triggering preordering of additional staining prior to the pathologist’s review — ultimately shortening the time needed to complete the pathology reporting.
“Together, these benefits can vastly improve overall care for patients waiting for results of their gastric biopsies,” she added.
Read more about